Featured Research

from universities, journals, and other organizations

New approaches needed for treating chronic myeloid leukemia

Date:
December 13, 2010
Source:
Journal of Clinical Investigation
Summary:
The drug imatinib transformed chronic myeloid leukemia (CML) from a fatal disease to a chronic condition. However, imatinib must be taken lifelong, because it fails to kill a residual number of CML cells. New research, has now determined why these cells don't respond to imatinib -- they do not need the protein imatinib targets for their survival. Therefore, new approaches are needed if further advances are to be made in the care of CML patients.

The drug imatinib transformed chronic myeloid leukemia (CML) from a fatal disease to a chronic condition. However, imatinib must be taken lifelong, because it fails to kill a residual number of CML cells. New research, has now determined why these cells don't respond to imatinib -- they do not need the protein imatinib targets for their survival. Therefore, new approaches are needed if further advances are to be made in the care of CML patients.

Chronic myeloid leukemia (CML) was transformed from a fatal disease to a chronic condition by the development of a drug known as imatinib, which targets the protein that drives this disease (BCR-ABL).

However, imatinib does not cure patients, they must take the drug lifelong, as disease recurs if they stop taking it. This is because imatinib does not kill all the CML cells; some, which are known as CML stem cells, persist. A key to therapeutically targeting CML stem cells is knowing whether they rely on BCR-ABL to persist. Answers to this will determine whether more effective BCR-ABL inhibitors are likely to be effective treatments or whether new approaches to targeting these cells need to be developed.

A team of researchers, led by Brian Drucker and Michael Deininger, at Oregon Health and Science University, Portland, has now shown clearly that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. As noted by the authors and, in an accompany commentary, Alexander Perl and Martin Carroll, at the University of Pennsylvania, Philadelphia, the data indicate that therapeutics targeting BCR-ABL will not improve CML treatment and that new approaches are needed if further advances in patient care are to be made.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal References:

  1. Alexander Perl and Martin Carroll. BCR-ABL kinase is dead; long live the CML stem cell. Journal of Clinical Investigation, 2010 DOI: 10.1172/JCI43605
  2. Amie S. Corbin, Anupriya Agarwal, Marc Loriaux, Jorge Cortes, Michael W. Deininger and Brian J. Druker. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. Journal of Clinical Investigation, 2010 DOI: 10.1172/JCI35721

Cite This Page:

Journal of Clinical Investigation. "New approaches needed for treating chronic myeloid leukemia." ScienceDaily. ScienceDaily, 13 December 2010. <www.sciencedaily.com/releases/2010/12/101213121702.htm>.
Journal of Clinical Investigation. (2010, December 13). New approaches needed for treating chronic myeloid leukemia. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2010/12/101213121702.htm
Journal of Clinical Investigation. "New approaches needed for treating chronic myeloid leukemia." ScienceDaily. www.sciencedaily.com/releases/2010/12/101213121702.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins